Following the announcement of Curasight's selection of brain cancer (glioblastoma) as the first indication for uTREAT® with enrolment of the first patient in Q2 2025 and the publication of an additional uTREAT® patent application securing protection until 2043, as well as the publication of the Q3 report, SEB has published an update as part of its coverage of Curasight.

According to the research note "Curasight showed disciplined cost control in Q3, tracking below our cost forecast for FY-24, and will now carry out the second warrant exercise, with the outcome on 9 December 2024. It should have patent protection for uTREAT through 2043, after submitting a new method-of-use patent, but more importantly, it plans to submit a Clinical Trial Application for high-grade glioma in early Q1 2025, and to dose the first patient in Q2 2025."

Based on this, SEB keeps the valuation range midpoint unchanged at DKK 54 per share.

"We are pleased that SEB clearly states a current valuation of Curasight shares that is almost 5 times higher than the price of the shares when bought with TO2 warrants. We therefore hope that our investors holding TO2 warrants will not only exercise them as a good investment, but also to support Curasight's plans to generate proof-of-concept data in brain tumour patients with uTREAT®," says CEO Ulrich Krasilnikoff.

For more information about Curasight:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.